-
Mashup Score: 5
Myeloma Paper of the Day, April 26th, suggested by Robert Orlowski / AL Amyloidosis, amyloidosis, blood advances, cancer, CHIP, clonal hematopoiesis, Clonal
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 40Clonal Hematopoiesis of Indeterminate Potential in Patients with Immunoglobulin Light Chain AL Amyloidosis - PubMed - 2 day(s) ago
Immunoglobulin light chain (AL) amyloidosis is characterized by the deposition of misfolded monoclonal free light chains, with cardiac complications accounting for patients’ mortality. Clonal hematopoiesis of indeterminate potential (CHIP) has been associated with worse cardiovascular outcomes in th …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 8
Myeloma Paper of the Day, April 25th, suggested by Robert Orlowski / cancer, MajesTEC-1 trial, MD Anderson Cancer Center, multiple myeloma, Myeloma, Myeloma
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2
Myeloma Paper of the Day, April 22nd, suggested by Robert Orlowski / BRAF mutations, cancer, KRAS mutation, MD Anderson Cancer Cente, monoclonal plasma cell
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 1
Myeloma Paper of the Day, April 21st, suggested by Robert Orlowski / BCMA CAR-T cell therapy, cancer, CD19 CAR-T cells, MD Anderson Cancer Center, multiple
Source: oncodaily.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 34Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium - PubMed - 13 day(s) ago
Real-world impact of bridging therapy on outcomes of ide-cel for myeloma in the U.S. Myeloma Immunotherapy Consortium
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
#Myeloma Paper of the Day: Study of real world impact of bridging therapy prior to CAR T finds response showed no significant association with CRS, ICANS rates, or 3-month post-CAR-T response, and median PFS didn’t significantly differ based on response: https://t.co/gzVPac99bJ. https://t.co/6fGX2MdpxV
-
-
Mashup Score: 4Analysis of @Myeloma_Doc FOLLOWERS - 19 day(s) ago
Map of Myeloma_Doc X (Twitter) followers.
Source: fedica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2What if you don’t match? 4 things you should do - 1 month(s) ago
A physician who has worked with unmatched applicants explains how to make the most of the coming year and improve the odds of matching in the next cycle.
Source: www.ama-assn.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Analysis of @Myeloma_Doc FOLLOWERS - 2 month(s) ago
Map of Myeloma_Doc X (Twitter) followers.
Source: fedica.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 15Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients - PubMed - 2 month(s) ago
This study on anti-MAG neuropathy provides updated insights into the epidemiology of this disease, clinical profiles, and treatment approaches in Japan. Rituximab therapy, used for only one-third of the patients, demonstrated efficacy. During the final visit, a quarter of the patients were unable to …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet
RT @oncodaily: Myeloma Paper of the Day, April 26th, suggested by @Myeloma_Doc https://t.co/UzFu6AhaVK @BloodJournal | @ASH_hematology A…